Financial Report: Merck 2Q

Merck 2Q

2Q Revenues: $5.9 billion (-3%)

2Q Earnings: $1.6 billion (-12%)

YTD revenues: $11.3 billion (-5%)

YTD Earnings: $3.0 billion (-41%)

Comments: Worldwide sales of Singulair were $1.3 billion in the quarter (+ 16%). Combined sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $1.0 billion (-10%). Cozaar and Hyzaar sales were $906 million (-4%). Gardasil sales were $268 million (-18%). Rotateq sales were $126 million (-29%). Januvia sales were up 38% to $462 million. Isentress sales were $172 million (+123%). Revenue from the AstraZeneca alliance for certain products including Nexium, was $386 million in the quarter. Restructuring costs in the quarter, primarily related to employee separations, were $37 million. R&D expenses were $1.4 billion for the quarter (+19%), reflecting an increase in the company’s external licensing activity.

Sign up today for Contracting & Outsourcing 2009!
dhruv_cp.rodpub.com/2009conference